Table 1

Baseline characteristics of the study subjects

Variable

Study group

P value

Hyal-Joint^® (n = 11)

Placebo (n = 9)

Men/women

4/7

5/4

0.653

Age, years, mean (SD)

57.7 (10.1)

54.6 (7.7)

0.448

Ethnicity

0.361

Black

0

1

Caucasian

1

1

Hispanic

10

6

Height, cm, mean (SD)

164.7 (6.1)

164.1 (10.8)

0.889

Weight, kg, mean (SD

79.1 (26.3)

80.9 (20.7)

0.867

Heart rate, beats/min, mean (SD)

75.5 (12.3)

75.7 (12.4)

0.970

Systolic BP, mm Hg, mean (SD)

122.8 (16.4)

135.6 (21.7)

0.152

Diastolic BP, mm Hg, mean (SD)

77.8 (8.9)

84.3 (10.4)

0.148

Rescue medication use (paracetamol 500 mg)*

No. capsules (range)

4 (0–19)

9 (0–29)

0.425

Mean (SD)

6.8 (7.3)

9.9 (9.6)

WOMAC scores, mean (SD)

Pain

10.4 (3.0)

10.1 (2.7)

0.848

Stiffness

4.4 (1.0)

4.4 (1.0)

0.862

Physical function

37.7 (7.4)

35.4 (11.5)

0.597

Aggregated total symptoms

52.5 (10.8)

50.0 (14.4)

0.667

SF-36v2 scores, mean (SD)

Physical functioning

30.8 (8.5)

27.1 (8.5)

0.342

Role-physical

35.3 (8.3)

41.9 (7.8)

0.084

Bodily pain

33.2 (4.8)

36.9 (4.8)

0.100

General health

44.1 (12.3)

45.4 (10.3)

0.814

Vitality

49.0 (11.3)

50.4 (11.7)

0.791

Social functioning

37.5 (12.0)

43.5 (11.3)

0.268

Role-emotional

36.1 (12.6)

40.3 (12.9)

0.467

Mental health

40.3 (19.7)

47.5 (9.5)

0.326

Physical component summary (PCS-36)

34.8 (6.3)

34.6 (6.4)

0.947

Mental component summary (MCS-36)

43.6 (17.5)

50.6 (11.2)

0.317

*Between screening and randomization visits.

Kalman et al. Nutrition Journal 2008 7:3   doi:10.1186/1475-2891-7-3